42593-13-5

Upstream product

• 611-10-9 2-ethoxycarbonyl-1-cyclopentanone 
• 42593-11-3 ethyl 1-bromo-2-oxocyclopentanecarboxylate 
• 42593-09-9 Ethyl 2-acetoxy-1-cyclopentene-1-carboxylate 

Downstream Products

• 130560-89-3 ethyl 2-phenyl-5,6-dihydro-4H-cyclopenta[d]thiazole-4-carboxylate 
• 1190387-74-6 (R)-2-amino-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]thiazole-4-carboxamide 
• 1190393-20-4 (S)-2-amino-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]thiazole-4-carboxamide 
• 1190391-17-3 (R)-2-amino-N-(4-(((2S,5R)-5-((R)-(3-chlorophenyl)(hydroxy)methyl)pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]thiazole-4-carboxamide 
• 1190391-02-6 (R)-2-amino-N-(4-(((2S,5R)-5-((R)-(3-fluorophenyl)(hydroxy)-methyl)pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]thiazole-4-carboxamide 
• 1190391-08-2 (R)-2-amino-N-(4-(((2S,5R)-5-((R)-(4-fluorophenyl)(hydroxy)methyl)pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]thiazole-4-carboxamide 
• 1190389-58-2 (R)-N-(4-(((2S,5R)-5-((R)-hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]thiazole-4-carboxamide 
• 1190393-18-0 C₃₅H₄₄N₄O₆S 
• 1190393-19-1 C₃₅H₄₄N₄O₆S 
• 1190613-43-4 (R)-N-(4-(((2S,5R)-5-((R)-hydroxy(pyridin-3-yl)methyl)pyrrolidin-2-yl)methyl)phenyl)-5,6-dihydro-4H-cyclopenta[d]thiazole-4-carboxamide 
• 1558057-87-6 C₃₅H₄₃ClN₄O₆S 
• 1558057-88-7 C₃₅H₄₃ClN₄O₆S 
• 1558057-89-8 C₃₅H₄₃FN₄O₆S 
• 1558057-90-1 C₃₅H₄₃FN₄O₆S 

Relevant academic research and scientific papers

THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY

The present invention relates to certain thiazolopyrimidinone compounds for use in modulating NMDA receptor activity, pharmaceutical compositions comprising such compounds and methods of treating neurological and psychiatric conditions.

Design, synthesis, and evaluation of conformationally restricted acetanilides as potent and selective β3 adrenergic receptor agonists for the treatment of overactive bladder

A series of conformationally restricted acetanilides were synthesized and evaluated as β3-adrenergic receptor agonists (β3-AR) for the treatment of overactive bladder (OAB). Optimization studies identified a five-membered ring as the preferred conformational lock of the acetanilide. Further optimization of both the aromatic and thiazole regions led to compounds such as 19 and 29, which have a good balance of potency and selectivity. These compounds have significantly reduced intrinsic clearance compared to our initial series of pyridylethanolamine β3-AR agonists and thus have improved unbound drug exposures. Both analogues demonstrated dose dependent β3-AR mediated responses in a rat bladder hyperactivity model.

HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

FUSED OXAZOLES and THIAZOLES AS HISTAMINE H3- RECEPTOR LIGANDS

The present invention relates to compounds comprising fused oxazole or thiazole derivatives of formula (I), processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H3-receptor ligands, wherein A is a cyclic amine which is linked to the propylene group via an amino nitrogen; B is selected from the group consisting of heteroaryl, 5-8-membered heterocycloalkyl, 5-8-membered cycloalkyl; X is either N or CH; Y is either O or S.

The synthesis of 5-substituted 6-oxo-2-piperidinecarboxylic acid derivatives from cyclopentanone-β-ketoesters

Ethyl 2-oxocyclopentanonecarboxylate was converted to 5-substituted 6-oxopiperidinecarboxylic derivatives via a synthetic sequence consisting of a) C-1-alkylation of the cyclopentanone-β-ketoester b) introduction of a protected amino group at the α'-position (C-3) of the cyclopentanone carbonyl group via bromination and substitution with phthalimide c) base promoted ring opening of the disubstuted cyclopentanone-β-ketoester to form the corresponding diester or ester-acid derivatives and d) final deprotection of the amino group with concomitant ring closure to produce the title compounds.